The numbers up front. A typical HSV-1 sufferer with 4 to 6 outbreaks per year currently spends between 230 and 410 USD per year managing them via the pharmacy path. Abreva at 18 to 22 USD per tube, used roughly 6 times. One or two GP visits for an antiviral prescription at 40 to 80 USD each. Occasional Acyclovir or Valacyclovir at 35 to 60 USD per course. Two missed work days from the worst outbreaks at an average loss of 180 USD each. The Labisan dual-protocol bundle costs 180 USD for a 3-month starter and 50 USD per month thereafter on maintenance, totalling 630 USD in year one and 600 USD per year on continuous use. On the surface the bundle looks more expensive. The honest comparison requires factoring in the month-12 outbreak frequency, where the pharmacy path is still 4 to 6 outbreaks per year and the Labisan path is roughly 1. By the time you account for the reduced outbreak count, the bundle saves 180 USD per year from year two onward, and most users continue indefinitely.
The pharmacy path, itemised
The conventional treatment plan for a typical recurrent HSV-1 sufferer involves three buckets of cost. Each one is small, which is why most people never add them up.
Topical cream per outbreak. Abreva (10 percent docosanol) at 18 to 22 USD per tube, used during the active outbreak. Most tubes do not finish during a single outbreak but the next outbreak is far enough away that the open tube has lost potency. Most sufferers buy a fresh tube each time. 6 outbreaks per year, 6 tubes, 120 USD annual spend.
Antiviral medication. A GP appointment to write a prescription costs 40 to 80 USD without insurance or 15 to 30 USD with most insurance copays. The Acyclovir or Valacyclovir course itself runs 35 to 60 USD generic, 80 to 140 USD brand. Sufferers who get this prescription typically do so 1 to 2 times per year for their worst outbreaks. Average annual spend 90 to 200 USD.
Lost productivity. The CDC estimates the average employed adult loses 1 to 3 work days per year specifically to HSV-1 outbreak management, photo-avoidance during peak visible stages, and reluctance to attend public meetings during the day-2 to day-4 vesicle stage. At a 60 USD per hour average professional wage in 2026, 2 missed days equals roughly 960 USD in pre-tax income or about 600 USD post-tax. Even half-counting this hidden cost adds 300 USD to the pharmacy-path total. Most sufferers do not include this on the ledger because they never have a clean control year to compare against.
Adding the three buckets: typical pharmacy-path sufferer spends 230 to 410 USD per year on a 4-to-6-outbreak baseline, with another 300 to 600 USD in hidden productivity cost.
The Labisan path, itemised
Starter bundle (months 1 to 3). One bottle of Labisan 22:1 Graviola Capsules (90 caps, 30 days at 3 caps maintenance or 22 days at 4 caps loading) plus one tube of Labisan Protective Lip Balm covers the first month at active-outbreak dosing. The 3-month starter bundle sized for the initial loading and stabilisation period prices at 180 USD.
Maintenance (months 4 onward). Two capsules per day is the long-term prevention dose, which is 60 capsules per 30 days, two thirds of a 90-cap bottle. One bottle of capsules every 45 days plus one lip balm tube every 60 days (used 2 times daily as morning SPF) totals roughly 50 USD per month on subscription.
Annual totals. Year 1 on Labisan: 180 USD starter plus 9 months at 50 USD = 630 USD. Year 2 onward: 12 months at 50 USD = 600 USD per year.
Where it gets interesting is the outbreak frequency change. By month 12 of continuous use, patient-observation pattern shows outbreak frequency falls from a 4-to-6 baseline to roughly 1 mild outbreak per year. That single remaining outbreak is also typically smaller, shorter, and easier to manage, with one tube of the topical sufficient to treat it and no need for a prescription escalation.
Side by side, year 1
Year 1 is the harder year because Labisan does not pay back its full benefit until the prevention dividend compounds. Even so, the year-1 math is closer than most people expect.
| Cost bucket | Pharmacy path | Labisan path |
|---|---|---|
| Topical cream per outbreak | 120 USD (6 tubes Abreva) | included in bundle |
| GP visit and antiviral prescription | 90 to 200 USD | 0 USD |
| Annual product subscription | 0 USD | 630 USD (starter plus 9 maintenance) |
| Lost work days (visible to user) | 300 to 600 USD (1 to 2 days) | roughly 75 to 150 USD (0.25 to 0.5 days) at month 12 outbreak rate |
| Total year 1 | 510 to 920 USD | 705 to 780 USD |
Year 1 net cost is roughly comparable. The Labisan path costs slightly more in pure dollars but produces fewer outbreaks (typically 3 in year 1 rather than 4 to 6) and the outbreaks that do occur are shorter, compressed from a 7-to-10-day visible course to a 5-day course on the protocol.
Side by side, year 2 and beyond
Year 2 onward is where the math separates. The pharmacy path stays flat. The Labisan path drops because the bundle is now just maintenance and outbreak frequency is at the new baseline.
| Cost bucket | Pharmacy path year 2 | Labisan path year 2 |
|---|---|---|
| Topical cream | 120 USD | included |
| Prescription | 90 to 200 USD | 0 USD |
| Annual subscription | 0 USD | 600 USD |
| Lost work days | 300 to 600 USD | 0 to 75 USD |
| Total year 2 | 510 to 920 USD | 600 to 675 USD |
The crossover happens. By year 2 the Labisan path produces 600 to 675 USD in total spend, while the pharmacy path remains at 510 to 920 USD. At the midpoint of each range (715 USD pharmacy vs 638 USD Labisan), the Labisan path is roughly 77 USD per year cheaper on direct cost and equivalent or better on outbreak count.
The hidden cost most people miss
The numbers above include 1 to 2 missed work days per year for the pharmacy path. This is on the conservative side. The more honest accounting also includes the cancelled dates, the skipped photos, the rescheduled meetings, the cancelled trips, and the chronic low-grade attention spent monitoring the lip and worrying about the next outbreak. These do not produce a line item on a spreadsheet but they produce a real cost on quality of life that the Labisan protocol meaningfully reduces.
One user described the year-12-month change as "I stopped checking my lip in mirrors." That is the unmeasured benefit. It does not show up in dollars but it shows up in the question "would I pay 50 USD per month to stop having this in the background of my life?" For most chronic HSV-1 sufferers the answer is yes once they have lived 12 months without it.
When the pharmacy path is the right choice
The Labisan bundle does not make sense for every user.
- If you get 1 or fewer outbreaks per year, your annual pharmacy spend is already 30 to 60 USD and the Labisan path would not save you money. A single tube of the Labisan topical bought as needed (60 USD) is a sensible upgrade over Abreva for the better resolution time, but the capsule maintenance is overkill for your case.
- If you have a specific medical contraindication to the graviola capsule (pregnancy, breastfeeding, certain Parkinson medications, low blood pressure with hypotensive medication), the systemic layer is not appropriate. The topical alone remains useful.
- If your insurance covers prescription antivirals with no copay and your outbreaks are infrequent, your effective pharmacy cost is much lower than the average and the math shifts back to the pharmacy path.
For everyone else who recognises a 4-to-6-outbreak annual pattern, the math favours the Labisan path from year 2 onward on direct dollars, and from year 1 onward on outbreak count and quality of life.
The simplest way to think about it
The Labisan bundle costs roughly 50 USD per month on continuous maintenance. The pharmacy path costs roughly 50 USD per month on a 6-outbreak baseline. The pure dollar cost is similar. What differs is what those 50 USD per month buy you. The pharmacy path manages the outbreaks you keep having. The Labisan path reduces the number of outbreaks you have so the same 50 USD buys you 1 mild outbreak per year rather than 6 painful ones.
If the goal is to spend less, the math is approximately a wash. If the goal is to have fewer outbreaks, the Labisan path wins by a 6-fold margin.
Both products are available individually on labisan.shop. The 3-month starter bundle is sized for the initial loading and stabilisation period that produces the 12-month dividend.
